LOS ANGELES, Feb. 16, 2006 (PRIMEZONE) -- CytoDyn, Inc. (OTCBB:CYDY) Research Report and WorldTalkRadio CEO interview is available from IPOdesktop.com and WorldTalkRadio, the Internet's leading talk station.
Interview guest: Allen D Allen, CEO
HIGHLIGHTS
-- CytoDyn created the AIDS drug Cytolin
-- The first targeted immune therapy for treating HIV/AIDS
-- That significantly reduced viral burden in preliminary studies.
CytoDyn IPOdesktop research report & WorldTalkRadio interview http://www.gaskinsco.com/linkto-cydy.shtml
CytoDyn CEO interview at WorldTalkRadio & IPOdesktop research report http://www.worldtalkradio.com/archive.asp?aid=6186
About http://IPOdesktop.com
IPOdesktop.com, the leading provider of independent IPO research for professional money managers and individual investors, also produces the IPO Hardball radio program.
In the 'Analysts Corner' at IPOdesktop.com, research reports are available for both recent IPOs and emerging companies.
http://gaskinsco.com/linkto-analysts-corner.htm
IPOdesktop editors are quoted by The Wall Street Journal, Dow Jones Newswires, MarketWatch, Reuters, USATODAY, and others. IPOdesktop editors also co-host financial programs at World Talk Radio, the largest Internet's Talk station.
Disclaimer
IPOdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this interview and research report, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made.
ID provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. ID has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so.
DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report and interview is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. ID has been compensated up to thirty five hundred dollars for preparation and posting of this report, radio interview, and other advertising services. This constitutes a conflict of interest as to ID's ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of ID do not own or trade equities under coverage. .more safe harbor & disclaimer http://gaskinsco.com/report-disclaimer-b.htm